Imperial College London Diabetes Centre, part of the M42 group, has rebranded as the Imperial College London Diabetes & Endocrine Centre (ICLDEC) to reflect its broader expertise across hormonal health and endocrinology.

Since opening in 2006, the centre has been a leading provider of diabetes care in the UAE. The new identity highlights its expanded focus on endocrine conditions such as metabolism, growth, fertility, and hormonal health. With more than 50 UK and US-certified endocrinologists, ICLDEC is the region’s largest hub for specialised care across four locations in Abu Dhabi, Al Ain, and Al Dhafra.

“This rebrand is a clear representation of the broad spectrum of care we provide,” said Dr Ali Anees, chief operating officer of M42’s global patient care platform in the UAE and Bahrain. “Endocrinology has always been a cornerstone of our services, and we’re reinforcing our leadership in both diabetes and broader endocrine care. By elevating the visibility of our endocrine expertise, we are reaffirming our leadership across both disciplines – a commitment that will be further underscored at our upcoming Diabetes & Endocrine Conference this November.”

With demand for endocrinology services rising, ICLDEC says it is expanding personalised and preventive approaches. This includes integrated care around weight management, following the UAE’s approval of GLP-1 weight-loss medications, alongside services such as pre- and post-bariatric care, medication plans, and wellness support.

“This rebrand is more than just a name change; it reflects our forward-looking vision and the ongoing achievements we strive for, ultimately, for the benefit of our patients,” added Dr Mai Al Jaber, chief executive officer of ICLDEC and M42’s outpatient care. “By expanding our scope, we ensure that we remain the trusted partner in endocrine care, not only across the UAE but throughout the wider region.”